Buy, Sell Or Hold: Dr Lal PathLabs, Metropolis Healthcare, Poly Medicure, Vijaya Diagnostic Centre, Syngene International — Analyst Forecast
- September 28, 2026
- Posted by: Ankit Jaiswal
- Category: Market
India’s listed healthcare stocks outside hospitals and drugmakers include diagnostics chains, medical device makers and contract research firms, businesses that tend to trade at premium multiples because of steady, recurring demand. This piece checks five such healthcare stocks on valuation and profitability, with hospitals and pharmaceuticals covered in their own sector pieces.
Sector Snapshot (28 September 2026)
| Stock | LTP (Rs) | 52W High | 52W Low | P/E vs Industry | ROE | Our View |
|---|---|---|---|---|---|---|
| Dr Lal PathLabs | 1,930.20 | 2,038.60 | 1,272.60 | 59.96 / 67.71 | 20.13% | Buy on Dips |
| Metropolis Healthcare | 569.10 | 609.05 | 412.25 | 59.48 / 67.71 | 12.56% | Hold |
| Poly Medicure | 1,665.40 | 2,094.30 | 1,182.00 | 55.86 / 67.71 | 10.37% | Hold |
| Vijaya Diagnostic Centre | 1,506.20 | 1,593.60 | 848.00 | 83.27 / 67.71 | 18.07% | Hold |
| Syngene International | 376.40 | 678.95 | 360.40 | 69.14 / 67.71 | 7.76% | Hold |
Quick Answer
Dr Lal PathLabs stands out among these healthcare stocks, trading below the industry average valuation while posting the strongest return on equity in the group and an almost debt-free balance sheet. The rest are holds: Metropolis Healthcare and Poly Medicure look reasonable but earn more modest returns, Vijaya Diagnostic Centre carries the richest multiple, and Syngene International’s steep fall has not made it cheap.
Click Here – Get Free Investment Predictions
Dr Lal PathLabs: Buy on Dips
Dr Lal PathLabs trades at Rs 1,930.20, down close to 5% from its 52-week high of Rs 2,038.60. It combines the strongest return on equity in this group at 20.13% with a price-to-earnings ratio of 59.96, below the industry average of 67.71, and a debt-to-equity ratio of just 0.08. That mix of solid profitability, a relative discount and a clean balance sheet makes it the standout among these healthcare stocks to accumulate on pullbacks, even though its absolute multiple is high.
Metropolis Healthcare: Hold
Metropolis Healthcare is at Rs 569.10, down close to 7% from its 52-week high of Rs 609.05. It trades at a price-to-earnings ratio of 59.48, below the industry average of 67.71, but a return on equity of 12.56% is modest for a multiple near 60. There is nothing alarming here, but nothing compelling enough to stand out either, which makes this a straightforward hold.
Poly Medicure: Hold
Poly Medicure, a maker of disposable medical devices, trades at Rs 1,665.40, down close to 20% from its 52-week high of Rs 2,094.30. Its price-to-earnings ratio of 55.86 is below the industry average of 67.71, but its return on equity of 10.37% is on the weaker side, and the balance sheet is clean with a debt-to-equity ratio of 0.11. That combination of a relative discount but modest returns keeps this in hold territory.
Vijaya Diagnostic Centre: Hold
Vijaya Diagnostic Centre is at Rs 1,506.20, close to its 52-week high of Rs 1,593.60 after climbing sharply from its low of Rs 848.00. It posts a healthy return on equity of 18.07%, but its price-to-earnings ratio of 83.27 is the richest in this group, well above the industry average of 67.71. With the stock near its highs on a stretched multiple, this looks like a hold rather than a fresh buy.
Syngene International: Hold
Syngene International, a contract research and manufacturing services company, trades at Rs 376.40, close to its 52-week low of Rs 360.40 and down close to 45% from its high of Rs 678.95. Its price-to-earnings ratio of 69.14 is still slightly above the industry average of 67.71, while its return on equity of 7.76% is the weakest in this group. A steep price drop does not automatically make a stock cheap, so this is a hold to watch for an earnings recovery rather than a buy on the fall alone.
Explore Univest’s stock screener to compare healthcare stocks on your own filters
What Ties These Healthcare Stocks Together
All five of these healthcare stocks trade between roughly 56 and 83 times earnings, reflecting the market’s appetite for defensive, recurring demand in diagnostics, devices and research services. Dr Lal PathLabs is the only one pairing a below-industry multiple with strong profitability, while the others either earn more modest returns or already price in a lot of growth. Test volumes, pricing pressure from online diagnostic players, export demand for medical devices and global pharma outsourcing trends can all move these numbers meaningfully from one quarter to the next.
Track live prices for these healthcare stocks anytime with the Univest iOS App and Univest Android App
Conclusion
Healthcare stocks in India remain broadly priced for steady growth. Dr Lal PathLabs currently looks best placed for gradual accumulation among these healthcare stocks, while Metropolis Healthcare, Poly Medicure, Vijaya Diagnostic Centre and Syngene International are more reasonable holds given their fuller valuations relative to current profitability. As always, treat this as a starting point rather than a final word.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Stock market investments are subject to market risks. Please verify all data independently and consult a SEBI-registered investment adviser before making any investment decisions. Univest Financial Services Private Limited, SEBI Registered Investment Adviser, Registration No. INH000013776.
Frequently Asked Questions
A few common questions on these healthcare stocks, answered briefly below for quick reference.
Which healthcare stocks look attractive right now?
Dr Lal PathLabs shows the most favourable combination of a below-industry valuation, the strongest return on equity and an almost debt-free balance sheet among these healthcare stocks.
Why do healthcare stocks trade at such high valuations?
Diagnostics, devices and research services benefit from steady, recurring demand and high margins, which has led the market to price them at 55 to 85 times earnings, well above most other sectors.
Is Syngene International cheap after falling 45%?
Not yet, since Syngene International still trades slightly above the industry average price-to-earnings ratio while its return on equity of 7.76% is the weakest among these healthcare stocks.
Why is Vijaya Diagnostic Centre rated a hold?
Vijaya Diagnostic Centre trades at the richest multiple in this group and close to its 52-week high, so even its strong 18.07% return on equity is already reflected in the price.
Are hospitals and pharma companies included here?
No, hospital operators and pharmaceutical makers are covered in their own sector pieces, so this list focuses on diagnostics, medical devices and research services.
Where can I track these healthcare stocks in real time?
You can track live prices, set price alerts, and follow quarterly results for Dr Lal PathLabs, Metropolis Healthcare, Poly Medicure, Vijaya Diagnostic Centre and Syngene International using the Univest iOS App and Univest Android App.
